Stock Performance and Market Context
On 1 September 2026, Shree Ganesh Biotech India Ltd’s share price settled at Rs.0.49, down 37.5% from its 52-week high of Rs.0.80. This price represents the lowest level ever recorded for the stock, underscoring the severity of its downtrend. Despite this, the stock marginally outperformed its sector by 0.31% on the day, though it remained below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling persistent selling pressure.
Comparatively, the stock’s one-day performance was flat at 0.00%, slightly underperforming the Sensex’s 0.02% gain. Over longer periods, the stock’s returns have been notably weak: a 9.09% decline over the past month versus a 1.44% drop in the Sensex, a 16.67% fall over three months compared to a 3.64% gain in the benchmark, and a 33.33% loss over the last year against the Sensex’s 4.22% decline. Year-to-date, the stock is down 19.35%, nearly double the Sensex’s 9.68% fall. Over three and five years, the stock has plunged 50.00% and 92.69% respectively, while the Sensex has risen 17.72% and 34.25% in the same periods.
Financial Health and Profitability Metrics
Shree Ganesh Biotech India Ltd’s financial indicators reveal a challenging environment. The company reported its lowest quarterly PBDIT at a negative Rs.0.89 crore and a corresponding PBT less other income also at Rs. -0.89 crore. Earnings per share for the quarter stood at a minimal negative Rs.0.01, reflecting limited profitability.
Over the past year, the company’s profits have contracted by 86%, contributing to its negative EBITDA of Rs. -1.76 crore. This negative earnings before interest, taxes, depreciation and amortisation figure highlights ongoing difficulties in generating operational cash flow. The company’s average return on equity (ROE) is a modest 2.62%, indicating low profitability relative to shareholders’ funds.
Debt servicing capacity remains weak, with an average EBIT to interest ratio of 0.35x, signalling that earnings before interest and tax cover interest expenses by a narrow margin. Despite this, the company maintains a net cash position, with an average net debt to equity ratio of -0.12, reflecting minimal leverage. The capital structure is rated as good, but overall quality assessments place the company below average due to its financial performance and growth metrics.
Valuation and Technical Indicators
The stock’s valuation multiples further illustrate its current status. The price-to-book value ratio stands at 0.31x, suggesting the market values the company at less than one-third of its book value. The EV/EBITDA and EV/EBIT ratios are both negative at -6.90x, consistent with the company’s loss-making status. The price-to-earnings ratio is not applicable due to negative earnings, and the PEG ratio is similarly unavailable.
Dividend metrics are absent, with no dividend yield or payout recorded, reflecting the company’s constrained cash flow and earnings.
Technically, the stock is entrenched in a bearish trend, which shifted from mildly bearish on 16 June 2026 at a price of Rs.0.58. Key technical indicators such as MACD and KST are bearish on both weekly and monthly timeframes, while Bollinger Bands signal mild to strong bearishness. The stock’s immediate support is at the current 52-week low of Rs.0.49, with resistance levels at Rs.0.52 (20-day moving average), Rs.0.58 (100-day moving average), and Rs.0.60 (200-day moving average). The 52-week high of Rs.0.80 remains a distant resistance point.
Shareholding and Quality Assessment
The majority of Shree Ganesh Biotech India Ltd’s shares are held by non-institutional investors, with institutional holdings at a low 1.42%. The company has no promoter share pledging, which is a positive aspect amid its financial difficulties.
Quality assessments rate the company as below average overall, with specific concerns in management risk and growth, while capital structure is considered good. Over the past five years, sales have declined by 31.22%, and EBIT has contracted sharply by 204.98%. The company’s average return on capital employed (ROCE) is weak at 1.52%, and tax ratio stands at zero, indicating no tax payments in recent periods.
Short-Term Financial Trends
Recent quarterly results show a flat trend, with key metrics at their lowest levels. The PBDIT and PBT less other income both recorded their lowest quarterly values at Rs. -0.89 crore, while EPS also hit a quarterly low of negative Rs.0.01. These figures underscore the continuing financial strain faced by the company.
Summary
Shree Ganesh Biotech India Ltd’s stock reaching an all-time low of Rs.0.49 on 1 September 2026 reflects a prolonged period of financial underperformance and market challenges. The company’s weak profitability, negative EBITDA, and poor debt servicing capacity contribute to its current valuation and technical positioning. Despite maintaining a net cash position and a good capital structure, the overall quality and growth metrics remain below average. The stock’s bearish technical trend and significant underperformance relative to the Sensex and its sector highlight the severity of the situation.
